Who Paid My Doc
Noxafil
Drug Infectious Disease
NDC 0085-4331-01
General payments
$228,175
Research payments
$1,865,421
Through program year 2025, $228,175 in general payments and $1,865,421 in research payments were reported against Noxafil (Infectious Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,395 | 1 |
| 2025 | Research | $44,894 | 8 |
| 2024 | General | $1,000 | 1 |
| 2024 | Research | $475,782 | 7 |
| 2023 | General | $1,628 | 1 |
| 2023 | Research | $392,444 | 44 |
| 2022 | Research | $217,475 | 33 |
| 2021 | General | $1,913 | 1 |
| 2021 | Research | $224,711 | 25 |
| 2020 | General | $21,859 | 20 |
| 2020 | Research | $227,572 | 154 |
| 2019 | General | $200,381 | 446 |
| 2019 | Research | $282,543 | 80 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
470 general · 351 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.